Nachrichten zur Coherus BioSciences Aktie

Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript

…

Coherus BioSciences Aktie: Verstärkter Wettbewerbsdruck spürbar

Coherus BioSciences, ein auf Biosimilars und Immunonkologie spezialisiertes Unternehmen, steht derzeit vor erheblichen Herausforderungen. Die Aktie des in Redwood City…

Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript

…

Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript

…

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -540% and 24.45%, respectively, for the quarter ended March 2024. Do…

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the…

Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript

…

Erstes Produkt basierend auf der Sorrel(TM) tragbare Deviceplattform der LTS in den USA zugelassen

LTS Lohmann Therapie-Systeme AG: Andernach (ots) - Die LTS LOHMANN Therapie-Systeme AG („LTS"), ein führendes pharmazeutisches Technologieunternehmen, gab heute bekannt,…

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS),…

Biggest stock movers today: Boeing, Coherus BioSciences, Archer-Daniels-Midland, and more

…

Sandoz to acquire Cimerli business from Coherus BioSciences for $170M in all-cash deal

…

Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” Nasdaq: CHRS), today announced that…

Coherus BioSciences shares take off on FDA approval of drug delivery device

Coherus BioSciences (NASDAQ:CHRS) shares gained more than 20% in early trade on Wednesday after it revealed that the United States…

These Stocks Are Moving the Most Today: Intel, Tesla, Apple, NetEase, Coherus BioSciences, and More

…

Intel, Tesla, Apple, NetEase, Coherus BioSciences, and More Stock Market Movers

Intel shares extend gains while Apple stock has declined for four straight sessions. A report says Tesla plans a revamped…

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS),…

Coherus BioSciences announces departure of finance chief McDavid Stilwell

…

Coherus BioSciences Announces CFO Transition Plans

REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that…

Coherus BioSciences, Inc. (CHRS) Q3 2023 Earnings Call Transcript

…

Coherus BioSciences to Participate at Upcoming November Investor Conferences

REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that…

Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023

REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that…

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS),…

Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the…

Ophthalmic Drugs Market Aims for Remarkable Growth, Targeting USD 62.67 Billion by 2032 at 6% CAGR

The global ophthalmic drugs market size is anticipated to grow from USD 35 billion to USD 62.67 billion in 10…

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS),…

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS),…

Why Coherus BioSciences Stock Popped Today

The immuno-oncology leader delivered a strong second quarter....…

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 26.92% and 15.53%, respectively, for the quarter ended June 2023. Do…

Form 10-Q Coherus BioSciences, For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., July 21, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS),…

Form 8-K Coherus BioSciences, For: Jul 18

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Lightning Round: Icahn Enterprises probably has another 10% higher to go, says Jim Cramer

'Mad Money' host Jim Cramer weighs in on stocks including: Icahn Enterprises, Rambus, Palantir, Commercial Metals and Coherus....…

Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.

–$995 per carton (two 40 mg/0.8 mL autoinjectors) represents a discount of more than 85% compared to Humira® –...…

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS),…

Coherus BioSciences acquiring Surface Oncology in up to $65M deal

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Surface Oncology stock rallies on all-stock acquisition by Coherus

Surface Oncology Inc. SURF stock is up 49% in premarket trades on Friday after the cancer drug company agreed to…

Coherus BioSciences to Buy Surface Oncology For Up to $65 Million

Coherus BioSciences to Buy Surface Oncology For Up to $65 Million...…

Coherus to Acquire Surface Oncology

– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical…

Form 8-K Coherus BioSciences, For: Jun 15

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

UPDATE 1-Coherus resolves part of dispute with AbbVie over Humira biosimilar

... in paragraph 6) June 15 (Reuters) - Coherus BioSciences said......…

AbbVie, Coherus in legal battle over Humira biosimilar

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Abbvie, Coherus agree to resolve dispute over Humira biosimilar

...(Reuters) - Coherus BioSciences Inc said on Thursday it had... the licensing agreement. AbbVie did not…

Form 8-K Coherus BioSciences, For: Jun 14

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Coherus BioSciences, For: Jun 07

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Coherus reports survival data from toripalimab Phase 3 study

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma

– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal…

dpa-AFX ProFeed